206 related articles for article (PubMed ID: 26748872)
1. Long-term efficacy of rituximab in IgM anti-myelin-associated glycoprotein neuropathy: RIMAG follow-up study.
Iancu Ferfoglia R; Guimarães-Costa R; Viala K; Musset L; Neil J; Marin B; Léger JM
J Peripher Nerv Syst; 2016 Mar; 21(1):10-4. PubMed ID: 26748872
[TBL] [Abstract][Full Text] [Related]
2. Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein antibody demyelinating neuropathy.
Dalakas MC; Rakocevic G; Salajegheh M; Dambrosia JM; Hahn AF; Raju R; McElroy B
Ann Neurol; 2009 Mar; 65(3):286-93. PubMed ID: 19334068
[TBL] [Abstract][Full Text] [Related]
3. Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein neuropathy.
Léger JM; Viala K; Nicolas G; Créange A; Vallat JM; Pouget J; Clavelou P; Vial C; Steck A; Musset L; Marin B;
Neurology; 2013 Jun; 80(24):2217-25. PubMed ID: 23667063
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy for IgM anti-myelin-associated glycoprotein paraprotein-associated peripheral neuropathies.
Lunn MP; Nobile-Orazio E
Cochrane Database Syst Rev; 2016 Oct; 10(10):CD002827. PubMed ID: 27701752
[TBL] [Abstract][Full Text] [Related]
5. Predictors of response to rituximab in patients with neuropathy and anti-myelin associated glycoprotein immunoglobulin M.
Benedetti L; Briani C; Grandis M; Vigo T; Gobbi M; Ghiglione E; Carpo M; Cocito D; Caporale CM; Sormani MP; Mancardi GL; Nobile-Orazio E; Schenone A
J Peripher Nerv Syst; 2007 Jun; 12(2):102-7. PubMed ID: 17565535
[TBL] [Abstract][Full Text] [Related]
6. Anti-MAG antibodies in 202 patients: clinicopathological and therapeutic features.
Svahn J; Petiot P; Antoine JC; Vial C; Delmont E; Viala K; Steck AJ; Magot A; Cauquil C; Zarea A; Echaniz-Laguna A; Iancu Ferfoglia R; Gueguen A; Magy L; Léger JM; Kuntzer T; Ferraud K; Lacour A; Camdessanché JP;
J Neurol Neurosurg Psychiatry; 2018 May; 89(5):499-505. PubMed ID: 29070644
[TBL] [Abstract][Full Text] [Related]
7. [Rapid improvement by rituximab treatment in a case of demyelinating polyneuropathy with anti-myelin-associated glycoprotein antibody].
Motoyama R; Yamakawa K; Suzuki S; Kusunoki S; Tanaka M
Rinsho Shinkeigaku; 2011 Oct; 51(10):761-4. PubMed ID: 22019868
[TBL] [Abstract][Full Text] [Related]
8. Axonal loss influences the response to rituximab treatment in neuropathy associated with IgM monoclonal gammopathy with anti-myelin-associated glycoprotein antibody.
Kawagashira Y; Koike H; Ohyama K; Hashimoto R; Iijima M; Adachi H; Katsuno M; Chapman M; Lunn M; Sobue G
J Neurol Sci; 2015 Jan; 348(1-2):67-73. PubMed ID: 25467141
[TBL] [Abstract][Full Text] [Related]
9. Acute neurological worsening after Rituximab treatment in patients with anti-MAG neuropathy.
Sala E; Robert-Varvat F; Paul S; Camdessanché JP; Antoine JC
J Neurol Sci; 2014 Oct; 345(1-2):224-7. PubMed ID: 25115501
[TBL] [Abstract][Full Text] [Related]
10. Neurophysiological and clinical responses to rituximab in patients with anti-MAG polyneuropathy.
Zara G; Zambello R; Ermani M
Clin Neurophysiol; 2011 Dec; 122(12):2518-22. PubMed ID: 21680240
[TBL] [Abstract][Full Text] [Related]
11. High-dose rituximab and anti-MAG-associated polyneuropathy.
Renaud S; Fuhr P; Gregor M; Schweikert K; Lorenz D; Daniels C; Deuschl G; Gratwohl A; Steck AJ
Neurology; 2006 Mar; 66(5):742-4. PubMed ID: 16534115
[TBL] [Abstract][Full Text] [Related]
12. Deterioration of tremor after treatment with rituximab in anti-MAG neuropathy.
Doneddu PE; Kazmi M; Samuel M; Mahdi-Rogers M; Hadden RDM
J Neurol Sci; 2017 Feb; 373():344-345. PubMed ID: 28131219
[No Abstract] [Full Text] [Related]
13. Long-term effect of rituximab in anti-mag polyneuropathy.
Benedetti L; Briani C; Franciotta D; Carpo M; Padua L; Zara G; Zambello R; Sormani MP; Mancardi GL; Nobile-Orazio E; Schenone A
Neurology; 2008 Nov; 71(21):1742-4. PubMed ID: 19015493
[No Abstract] [Full Text] [Related]
14. Immunotherapy for IgM anti-myelin-associated glycoprotein paraprotein-associated peripheral neuropathies.
Lunn MP; Nobile-Orazio E
Cochrane Database Syst Rev; 2012 May; (5):CD002827. PubMed ID: 22592686
[TBL] [Abstract][Full Text] [Related]
15. Long-term response to rituximab and fludarabine combination in IgM anti-myelin-associated glycoprotein neuropathy.
Gruson B; Ghomari K; Beaumont M; Garidi R; Just A; Merle P; Merlusca L; Marolleau JP; Royer B
J Peripher Nerv Syst; 2011 Sep; 16(3):180-5. PubMed ID: 22003932
[TBL] [Abstract][Full Text] [Related]
16. Limitations in daily activities and general perception of quality of life: Long term follow-up in patients with anti-myelin-glycoprotein antibody polyneuropathy.
Campagnolo M; Ruiz M; Falzone YM; Ermani M; Bianco M; Martinelli D; Cerri F; Quattrini A; Salvalaggio A; Castellani F; Comi G; Giannini F; Nobile-Orazio E; Fazio R; Riva N; Briani C
J Peripher Nerv Syst; 2019 Sep; 24(3):276-282. PubMed ID: 31397934
[TBL] [Abstract][Full Text] [Related]
17. Predictive factors of efficacy of rituximab in patients with anti-MAG neuropathy.
Gazzola S; Delmont E; Franques J; Boucraut J; Salort-Campana E; Verschueren A; Sagui E; Hubert AM; Pouget J; Attarian S
J Neurol Sci; 2017 Jun; 377():144-148. PubMed ID: 28477685
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of rituximab in anti-myelin-associated glycoprotein demyelinating polyneuropathy: Clinical, hematological and neurophysiological correlations during 2 years of follow-up.
Parisi M; Dogliotti I; Clerico M; Bertuzzo D; Benevolo G; Orsucci L; Schiavetti I; Cavallo R; Cavallo F; Ragaini S; Di Liberto A; Ferrante M; Bondielli G; Artusi CA; Drandi D; Lopiano L; Ferrero B; Ferrero S
Eur J Neurol; 2022 Dec; 29(12):3611-3622. PubMed ID: 36083713
[TBL] [Abstract][Full Text] [Related]
19. Obinutuzumab, a new anti-CD20 antibody, and chlorambucil are active and effective in anti-myelin-associated glycoprotein antibody polyneuropathy.
Briani C; Visentin A; Salvalaggio A; Cacciavillani M; Trentin L
Eur J Neurol; 2019 Feb; 26(2):371-375. PubMed ID: 30315672
[TBL] [Abstract][Full Text] [Related]
20. Detection of anti-MAG antibodies in polyneuropathy associated with IgM monoclonal gammopathy.
Kuijf ML; Eurelings M; Tio-Gillen AP; van Doorn PA; van den Berg LH; Hooijkaas H; Stork J; Notermans NC; Jacobs BC
Neurology; 2009 Sep; 73(9):688-95. PubMed ID: 19720975
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
